| Attitudes of patients with spondylarthritis or rheumatoid arthritis regarding biological treatment during COVID-19 pandemic: A multi-center, phone-based, cross-sectional study | Kenan AKGÜN, Coskun ZATERİ, Selda SARIKAYA, Lale ALTAN, Nurettin TAŞTEKİN, Şenay ÖZDOLAP, Nigar DURSUN, Reyhan ÇELİKER, Aylin REZVANİ, İlknur AKTAŞ, Murat BİRTANE | 473–481 |
| The plasma microRNA levels and their relationship with the general health and functional status in female patients with fibromyalgia syndrome | Didem Havva ÇELİKCAN, Ali BİÇER, Orhan GÜVENER, Ayşegül GÖRÜR, Lülüfer TAMER, Erbil AKASLAN | 482–492 |
| Differentiating children with familial Mediterranean fever from other recurrent fever syndromes: The utility of new Eurofever/PRINTO classification criteria | Atıl BİŞGİN, Dilek KARAGÖZ, Sibel BALCI, Rabia Miray Kışla EKİNCİ, Derya Ufuk ALTINCTAŞ, Ahmet Hakan EROL | 493–498 |
| Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea | You-Jung Ha, In Ah Choi, Ji Hyoun Kim, Sung Hae Chang, Ran Song, Hye Won Kim, Jeong Seok Lee, Byoongyong Choi, Yoon-Jeong Oh, Ki Won Moon | 499–509 |
| A preliminary study of possible fibrotic role of meprin metalloproteases in scleroderma patients | A. Merih BİRLİK, Ayşe KOÇAK, Duygu HARMANCI, Aydan Köken AVŞAR, Gül AKDOĞAN | 510–517 |
| Validity and reliability of the Turkish version of the central sensitization inventory | Galip EKUKLU, Ayşegül KETENCİ, Nurettin TAŞTEKİN, Cumhur KILINÇER, Okan ÇALIYURT, Enes Efe IS, Murat BİRTANE, Ela Düzce Keleş, Randy Neblett | 518–526 |
| Persistent eosinophilia and associated organ involvement in Thai patients with systemic sclerosis: Data from the Siriraj scleroderma cohort | Somsak Punjasamanvong, Chayawee Muangchan | 527–537 |
| Effect of childhood trauma on disease severity in patients with fibromyalgia: The mediating role of psychological resilience | Özlem Kazan KIZILKURT, Hüseyin Güleç, Ferzan Ergün Gıynaş, Arda Kazım Demirkan | 538–547 |
| Screening and identification of potential biomarkers and therapeutic targets for systemic sclerosis-associated interstitial lung disease | Biqing Huang, Jing Li, Jiuliang Zhao | 548–559 |